Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infectim
- Development stage
- Unknown
- Lead developer
- Astel Medica
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Infectim is a probiotic-based product line developed by Astel Medica, specifically formulated to support urogenital health by restoring the natural balance of the vaginal and intestinal flora. The product line includes Infectim (vaginal capsules) and Infectim+ (oral capsules), which contain specific strains of lactic acid bacteria such as *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, *Lactobacillus reuteri*, and *Streptococcus thermophilus*. These probiotics function by adhering to mucosal surfaces, producing lactic acid to maintain a low pH environment, and generating antimicrobial substances that inhibit the growth of pathogens like *Gardnerella vaginalis* and *Candida albicans*. Infectim is used for the prevention and treatment of vaginal dysbiosis, bacterial vaginosis, and yeast infections.
- Brand names
- InfectimInfectim+
- Other names
- Infectim Plus
Beyond the preview
Go deeper on Infectim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infectim.